13D Filing: Elliott Associates, L.P. and Cormedix Inc. (CRMD)

Page 5 of 8 – SEC Filing

The following constitutes Amendment No. 4 (“Amendment No. 4”) to the Schedule 13D filed by the undersigned (the “Schedule 13D”). This Amendment No. 4 amends the Schedule 13D as specifically set forth herein.
Item 3.
Source and Amount of Funds or Other Consideration.
Item 3 is hereby amended and restated to read as follows:
Elliott Working Capital
The aggregate purchase price of the shares of Common Stock indirectly owned by Elliott through Manchester Securities Corp., a wholly-owned subsidiary (“Manchester”) is approximately $1,280,000.
Elliott International Working Capital
The aggregate purchase price of the shares of Common Stock directly owned by Elliott International is approximately $2,720,000.
ITEM 5.
Interest in Securities of the Issuer.
Item 5(a) is hereby amended and restated in its entirety to read as follows:
(a) As of the date hereof, Elliott, Elliott International and EICA collectively may be deemed to beneficially own 5,928,080 shares of Common Stock, including 1,861,856 shares of Common Stock issuable upon the conversion or exercise, as the case may be, of certain convertible securities constituting approximately 9.9% of the shares of Common Stock outstanding calculated in accordance with the Ownership Limitation (as defined below) and based on a pro-rata conversion or exercise of such securities between the Reporting Persons.
The aggregate percentage of Common Stock reported owned by each person named herein is based upon 59,340,139 shares of Common Stock, which is the total number of shares outstanding as of March 14, as reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2017, including the shares to be offered as part of the Issuer’s Offering (as defined below) as reported on April 28, 2017 on the Prospectus Supplement (the “Prospectus Supplement”) filed  pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on April 28, 2017, assuming conversion of all the Reporting Person’s Preferred Stock calculated in accordance with the Ownership Limitation.
As of the date hereof, Elliott through Manchester may be deemed to beneficially own 1,976,027 shares of Common Stock, including 664,793 shares of Common Stock issuable upon the conversion or exercise, as the case may be, of certain convertible securities constituting approximately 3.3% of the shares of Common Stock outstanding, calculated in accordance with the Ownership Limitation and based on a pro-rata conversion or exercise of such securities between the Reporting Persons.
As of the date hereof, Elliott International may be deemed to beneficially own 3,952,053 shares of Common Stock, including 1,197,063 shares of Common Stock issuable upon the conversion or exercise, as the case may be, of certain convertible securities constituting approximately 6.6% of the shares of Common Stock outstanding, calculated in accordance with the Ownership Limitation and based on a pro-rata conversion or exercise of such securities between the Reporting Persons. EICA, as the investment manager of Elliott International may be deemed to beneficially own the 3,952,053 shares of Common Stock beneficially owned by Elliott International, constituting approximately 6.6% of the shares of Common Stock outstanding calculated in accordance with the Ownership Limitation and based on a pro-rata conversion or exercise of such securities between the Reporting Persons.

Follow Cormedix Inc. (NYSEMKT:CRMD)